Brivaracetam: A rational drug discovery success story

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Levetiracetam, the α-ethyl analogue of the nootropic piracetam, is a widely used antiepileptic drug (AED) that provides protection against partial seizures and is also effective in the treatment of primary generalized seizure syndromes including juvenile myoclonic epilepsy. Levetiracetam was discovered in 1992 through screening in audiogenic seizure susceptible mice and, 3 years later, was reported to exhibit saturable, stereospecific binding in brain to a ∼90 kDa protein, later identified as the ubiquitous synaptic vesicle glycoprotein SV2A. A large-scale screening effort to optimize binding affinity identified the 4-n-propyl analogue, brivaracetam, as having greater potency and a broadened spectrum of activity in animal seizure models. Recent phase II clinical trials demonstrating that brivaracetam is efficacious and well tolerated in the treatment of partial onset seizures have validated the strategy of the discovery programme. Brivaracetam is among the first clinically effective AEDs to be discovered by optimization of pharmacodynamic activity at a molecular target.

Original languageEnglish (US)
Pages (from-to)1555-1557
Number of pages3
JournalBritish Journal of Pharmacology
Volume154
Issue number8
DOIs
StatePublished - Aug 26 2008

Fingerprint

Drug Discovery
etiracetam
Seizures
Juvenile Myoclonic Epilepsy
Piracetam
Nootropic Agents
Phase II Clinical Trials
Synaptic Vesicles
Anticonvulsants
Glycoproteins
Animal Models
2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide
Brain
Therapeutics
Proteins

Keywords

  • λ-butyrolactam
  • Antiepileptic drug
  • Audiogenic seizures
  • Brivaracetam
  • Kindling
  • Levetiractam
  • Piracetam
  • Rational drug discovery
  • SV2A

ASJC Scopus subject areas

  • Pharmacology

Cite this

Brivaracetam : A rational drug discovery success story. / Rogawski, Michael A.

In: British Journal of Pharmacology, Vol. 154, No. 8, 26.08.2008, p. 1555-1557.

Research output: Contribution to journalArticle

@article{867efa64ed364263a0035298b909ce62,
title = "Brivaracetam: A rational drug discovery success story",
abstract = "Levetiracetam, the α-ethyl analogue of the nootropic piracetam, is a widely used antiepileptic drug (AED) that provides protection against partial seizures and is also effective in the treatment of primary generalized seizure syndromes including juvenile myoclonic epilepsy. Levetiracetam was discovered in 1992 through screening in audiogenic seizure susceptible mice and, 3 years later, was reported to exhibit saturable, stereospecific binding in brain to a ∼90 kDa protein, later identified as the ubiquitous synaptic vesicle glycoprotein SV2A. A large-scale screening effort to optimize binding affinity identified the 4-n-propyl analogue, brivaracetam, as having greater potency and a broadened spectrum of activity in animal seizure models. Recent phase II clinical trials demonstrating that brivaracetam is efficacious and well tolerated in the treatment of partial onset seizures have validated the strategy of the discovery programme. Brivaracetam is among the first clinically effective AEDs to be discovered by optimization of pharmacodynamic activity at a molecular target.",
keywords = "λ-butyrolactam, Antiepileptic drug, Audiogenic seizures, Brivaracetam, Kindling, Levetiractam, Piracetam, Rational drug discovery, SV2A",
author = "Rogawski, {Michael A}",
year = "2008",
month = "8",
day = "26",
doi = "10.1038/bjp.2008.221",
language = "English (US)",
volume = "154",
pages = "1555--1557",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Brivaracetam

T2 - A rational drug discovery success story

AU - Rogawski, Michael A

PY - 2008/8/26

Y1 - 2008/8/26

N2 - Levetiracetam, the α-ethyl analogue of the nootropic piracetam, is a widely used antiepileptic drug (AED) that provides protection against partial seizures and is also effective in the treatment of primary generalized seizure syndromes including juvenile myoclonic epilepsy. Levetiracetam was discovered in 1992 through screening in audiogenic seizure susceptible mice and, 3 years later, was reported to exhibit saturable, stereospecific binding in brain to a ∼90 kDa protein, later identified as the ubiquitous synaptic vesicle glycoprotein SV2A. A large-scale screening effort to optimize binding affinity identified the 4-n-propyl analogue, brivaracetam, as having greater potency and a broadened spectrum of activity in animal seizure models. Recent phase II clinical trials demonstrating that brivaracetam is efficacious and well tolerated in the treatment of partial onset seizures have validated the strategy of the discovery programme. Brivaracetam is among the first clinically effective AEDs to be discovered by optimization of pharmacodynamic activity at a molecular target.

AB - Levetiracetam, the α-ethyl analogue of the nootropic piracetam, is a widely used antiepileptic drug (AED) that provides protection against partial seizures and is also effective in the treatment of primary generalized seizure syndromes including juvenile myoclonic epilepsy. Levetiracetam was discovered in 1992 through screening in audiogenic seizure susceptible mice and, 3 years later, was reported to exhibit saturable, stereospecific binding in brain to a ∼90 kDa protein, later identified as the ubiquitous synaptic vesicle glycoprotein SV2A. A large-scale screening effort to optimize binding affinity identified the 4-n-propyl analogue, brivaracetam, as having greater potency and a broadened spectrum of activity in animal seizure models. Recent phase II clinical trials demonstrating that brivaracetam is efficacious and well tolerated in the treatment of partial onset seizures have validated the strategy of the discovery programme. Brivaracetam is among the first clinically effective AEDs to be discovered by optimization of pharmacodynamic activity at a molecular target.

KW - λ-butyrolactam

KW - Antiepileptic drug

KW - Audiogenic seizures

KW - Brivaracetam

KW - Kindling

KW - Levetiractam

KW - Piracetam

KW - Rational drug discovery

KW - SV2A

UR - http://www.scopus.com/inward/record.url?scp=49549119738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49549119738&partnerID=8YFLogxK

U2 - 10.1038/bjp.2008.221

DO - 10.1038/bjp.2008.221

M3 - Article

C2 - 18552880

AN - SCOPUS:49549119738

VL - 154

SP - 1555

EP - 1557

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 8

ER -